1. Home
  2. Companies
  3. OIL
  4. Material Events

Optiscan Imaging (ASX:OIL) — Material Events

ASX:OIL · 14 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 12 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
12
Optiscan Launches InSpecta™ in US Veterinary Market After FDA ApprovalMedium
Optiscan launches InSpecta™ veterinary imaging device in U.S. after FDA approval
7 July 2026 ·Product Launch and Regulatory Update ·85
Optiscan Accelerates Clinical Trials and FDA Prep with Key PartnershipsMedium
Optiscan advances clinical studies and partnerships, boosts cash receipts, and prepares for 2026 FDA submissions
30 Jan 2026 ·Quarterly Activities & Cashflow Report ·85
Optiscan Accelerates Clinical Trials and Expands Device Portfolio Amid Regulatory PushMedium
Optiscan advances clinical trials, unveils new devices, and strengthens US FDA regulatory pathway with Long Grove collaboration
31 July 2025 ·Appendix 4C Quarterly Cashflow and Activities Report ·85
Optiscan Raises $17.75m to Accelerate Clinical Trials and FDA Approval PathwayMedium
Optiscan raises $17.75m, advances clinical studies and FDA preparations with strong cash position
28 Oct 2025 ·Appendix 4C Quarterly Activities & Cashflow Report ·85
Optiscan lodges FDA dossier for InSpecta and advances clinical trials for US market pushHigh
Optiscan lodges FDA dossier for InSpecta®, advances clinical studies and prepares US veterinary market launch
30 Apr 2026 ·Quarterly Activities & Cashflow Report ·85
Optiscan Launches Pioneering Head and Neck Cancer Imaging Study in PerthMedium
Optiscan launches first-in-human head and neck cancer imaging study in Australia
3 Dec 2025 ·Clinical Study Initiation Announcement ·85
Optiscan Advances US Veterinary Market Entry with FDA Dossier SubmissionMedium
Optiscan submits FDA dossier for InSpecta®, advancing U.S. veterinary market entry
31 Mar 2026 ·Regulatory Submission Announcement ·85
Optiscan and ACL Join Forces to Revolutionize Real-Time Digital PathologyMedium
Optiscan and Australian Clinical Labs Partner to Advance Real-Time Digital Pathology
10 Nov 2025 ·Strategic Collaboration Announcement ·80
Optiscan Raises $17.75m to Accelerate FDA Approval and Market LaunchMedium
Optiscan launches $17.75m fully underwritten entitlement offer to fund clinical and regulatory milestones
27 Aug 2025 ·Capital Raising ·80
Optiscan Hits Halfway Point in Breast Cancer Imaging Study Ahead of FDA FilingsMedium
Optiscan reaches halfway recruitment milestone in breast cancer imaging study supporting FDA submissions
4 June 2026 ·Clinical Study Update ·75
Optiscan Raises $17.75M in Fully Underwritten Entitlement Offer to Advance Medical DevicesMedium
Optiscan launches $17.75M fully underwritten entitlement offer to fund clinical and regulatory development
27 Aug 2025 ·Entitlement Issue Prospectus ·75
Optiscan and Mayo Clinic Hit Two-Year Milestone in Robotic Surgery Imaging CollaborationMedium
Optiscan and Mayo Clinic mark two years of collaboration on robotic surgery imaging system
1 June 2026 ·Progress Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.